The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Genetic Neurodegenerative Diseases: The Human Illness and Transgenic Models
Abstract
The neurodegenerative disorders, a heterogeneous group of chronic progressive diseases, are among the most puzzling and devastating illnesses in medicine. Some of these disorders, such as Alzheimer's disease, amyotrophic lateral sclerosis, the prion diseases, and Parkinson's disease, can occur sporadically and, in some instances, are caused by inheritance of gene mutations. Huntington's disease is acquired in an entirely genetic manner. Transgenic mice that express disease-causing genes recapitulate many features of these diseases. This review provides an overview of transgenic mouse models of familial amyotrophic lateral sclerosis, familial Alzheimer's disease, and Huntington's disease and the emerging insights relevant to the underlying molecular mechanisms of these diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A major pathologic hallmark of AD is the deposition of the normally soluble A peptide into aggregated, extracellular structures called plaques (Price et al., 1998;Selkoe, 2001).”
From In Vivo Assessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-Life (2003) · cites this paper as Price et al., 1998
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Self-citationMACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy
Spada, A. R. L., Wilson, E. M., Lubahn, D. B., Harding, A. E., & Fischbeck, K. H. (1991) · Nature · doi:10.1038/352077a0 · Cited by 2,784
Cited by
Antioxidant enzymes and human diseases
MatÉs, J. M., Pérez-Gómez, C., & De Castro, I. N. (1999) · Clinical Biochemistry · doi:10.1016/s0009-9120(99)00075-2 · Cited by 2,099
Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology
Matés, >. M. (2000) · Toxicology · doi:10.1016/s0300-483x(00)00306-1 · Cited by 1,518
Stamer, K., Vogel, R., Thies, E., Mandelkow, E., & Mandelkow, E.-M. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200108057 · Cited by 885
Amyloid β-Induced Neuronal Hyperexcitability Triggers Progressive Epilepsy
Minkeviciene, R., Rheims, S., Dobszay, M. B., Zilberter, M., Hartikainen, J., Fülöp, L., Penke, B., Zilberter, Y., Harkany, T., Pitkänen, A., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5215-08.2009 · Cited by 652
Antioxidant enzymes and their implications in pathophysiologic processes
Mates, J. M. (1999) · Frontiers in Bioscience · doi:10.2741/a432 · Cited by 520
Li, C.-Y., Lee, J.-S., Ko, Y.-G., Kim, J.-I., & Seo, J.-S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m906383199 · Cited by 470
Drug delivery to mitochondria: the key to mitochondrial medicine
Murphy, M. P., & Smith, R. A. J. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(99)00069-1 · Cited by 426
Kane, M. D., Lipinski, W. J., Callahan, M. J., Bian, F., Durham, R. A., Schwarz, R. D., Roher, A. E., & Walker, L. C. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-10-03606.2000 · Cited by 394
“A growing body of evidence implicates the aggregation of misfolded proteins in the pathogenesis of amyloidoses, spongiform encephalopathies, and other neurodegenerative diseases in which protein accumulation is a common feature (Gajdusek, 1994; Olafsson et al., 1996; Carrell and Lomas, 1997; Kisilevsky and Fraser, 199…”
BackgroundInfluentialCirrito, J. R., May, P. C., O'Dell, M. A., Taylor, J. W., Parsadanian, M., Cramer, J. W., Audia, J. E., Nissen, J. S., Bales, K. R., Paul, S. M., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08844.2003 · Cited by 394
“A major pathologic hallmark of AD is the deposition of the normally soluble A peptide into aggregated, extracellular structures called plaques (Price et al., 1998; Selkoe, 2001).”
Backgroundβ‐Amyloid efflux mediated by p‐glycoprotein
Lam, F. C., Liu, R., Lu, P., Shapiro, A. B., Renoir, J., Sharom, F. J., & Reiner, P. B. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00113.x · Cited by 380
Hernández, F., Borrell, J., Guaza, C., Avila, J., & Lucas, J. J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01269.x · Cited by 372
Touma, C., Palme, R., & Sachser, N. (2004) · Hormones and Behavior · doi:10.1016/j.yhbeh.2003.07.002 · Cited by 370
Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease
Resende, R., Moreira, P. I., Proença, T., Deshpande, A., Busciglio, J., Pereira, C., & Oliveira, C. R. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.03.012 · Cited by 343
Genetic Classification of Primary Neurodegenerative Disease
Hardy, J., & Gwinn-Hardy, K. (1998) · Science · doi:10.1126/science.282.5391.1075 · Cited by 343
Lipid rafts, cholesterol, and the brain
Korade, Z., & Kenworthy, A. K. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.02.019 · Cited by 342
Protein misfolding and disease; protein refolding and therapy
Soto, C. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02486-3 · Cited by 336
Demars, M., Hu, Y., Gadadhar, A., & Lazarov, O. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22387 · Cited by 326
MicroRNAs (miRNAs) in Neurodegenerative Diseases
Nelson, P. T., Wang, W., & Rajeev, B. W. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00120.x · Cited by 326
The Role and Perspective of Ab Initio Molecular Dynamics in the Study of Biological Systems
Carloni, P., Rothlisberger, U., & Parrinello, M. (2002) · Accounts of Chemical Research · doi:10.1021/ar010018u · Cited by 312
Ando, K., Iijima, K.-I., Elliott, J. I., Kirino, Y., & Suzuki, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104059200 · Cited by 261
Engel, T., Hernández, F., Avila, J., & Lucas, J. J. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0604-06.2006 · Cited by 260
Buttini, M., Yu, G.-Q., Shockley, K., Huang, Y., Jones, B., Masliah, E., Mallory, M., Yeo, T., Longo, F. M., & Mucke, L. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-24-10539.2002 · Cited by 183
“…et al., 1993; Yankner, 1996; Klein et al., 2001), injected into the brain (Geula et al., 1998), or produced in neurons of transgenic mice (Games et al., 1995; Masliah et al., 1996, 2001; Nalbantoglu et al., 1997; Calhoun et al., 1998; Price et al., 1998; Hsia et al., 1999; Mucke et al., 2000).”
BackgroundTransgenic mouse models of Alzheimer's disease: phenotype and application.
(2003) · PubMed · doi:10.1097/01.fbp.0000088420.18414.ff · Cited by 147
“…of AD-associated genes has now revolutionized animal models of AD, in much the same way as for other neurodegenerative disorders of known genetic aetiology – such as motor neuron disease (amyotrophic lateral sclerosis, ALS) and Huntington’s disease (e.g. Price et al., 1998; Wong et al., 2002).”
BackgroundAraki, Y., Tomita, S., Yamaguchi, H., Miyagi, N., Sumioka, A., Kirino, Y., & Suzuki, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306024200 · Cited by 122
Exogenous induction of cerebral β-amyloidosis in βAPP-transgenic mice
Walker, L. C., Callahan, M. J., Bian, F., Durham, R. A., Roher, A. E., & Lipinski, W. J. (2002) · Peptides · doi:10.1016/s0196-9781(02)00059-1 · Cited by 96
Targeting Aβ and tau in Alzheimer's disease, an early interim report
Golde, T. E., Petrucelli, L., & Lewis, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.035 · Cited by 89
“In preclinical mouse models of Aβ deposition (APP transgenic mice), modification of the Aβ deposition phenotype and the modest cognitive/behavioral impairment exhibited in many of these mice has proven reasonably simple (Price et al., 1998).”
Complement in Alzheimer's disease: opportunities for modulating protective and pathogenic events
Tenner, A. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00301-3 · Cited by 81
Amyloid precursor protein increases cortical neuron size in transgenic mice
Oh, E. S., Savonenko, A. V., King, J. F., Fangmark Tucker, S. M., Rudow, G. L., Xu, G., Borchelt, D. R., & Troncoso, J. C. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.024 · Cited by 75
Self-citationLead (Pb) exposure and its effect on APP proteolysis and Aβ aggregation
Basha, M. R., Murali, M., Siddiqi, H. K., Ghosal, K., Siddiqi, O. K., Lashuel, H. A., Ge, Y., Lahiri, D. K., & Zawia, N. H. (2005) · The FASEB Journal · doi:10.1096/fj.05-4375fje · Cited by 74
Golde, T. E. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-8 · Cited by 71
“made by creating transgenic mice expressing the mutant genes in the brain [4,5].”
BackgroundSzapacs, M. E., Numis, A. L., & Andrews, A. M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.04.010 · Cited by 49
Artificial intelligence for dementia drug discovery and trials optimization
Doherty, T., Yao, Z., Khleifat, A. A. L., Tantiangco, H., Tamburin, S., Albertyn, C., Thakur, L., Llewellyn, D. J., Oxtoby, N. P., Lourida, I., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13428 · Cited by 48
Xu, G., Gonzales, V., & Borchelt, D. R. (2002) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200207000-00010 · Cited by 37
Self-citationHoldridge, K. C., Yaari, R., Hoban, D. B., Andersen, S., & Sims, J. R. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13031 · Cited by 19
Human iPSC Models in Drug Discovery: Opportunities and Challenges
Silva, M. C., Cross, A., Brandon, N. J., & Haggarty, S. J. (2017) · Comprehensive Medicinal Chemistry III · doi:10.1016/b978-0-12-409547-2.12284-x · Cited by 6
Covalent fragment inhibits intramembrane proteolysis
Eden, A., Zhao, J., Xiao, Y., Gibson, J., & Wang, C. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.958399 · Cited by 3
Metadata
- Authors
- Price, D. L., Sisodia, S. S., & Borchelt, D. R.
- Venue
- Science
- Published
- 1998-11-06
- Volume
- 282
- Issue
- 5391
- Pages
- 1079-1083
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2004782459
- Cited by
- 259
- References
- 111
- FWCI
- 19.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.